LXEO

LEXEO THERAPEUTICS INC

LXEO·52886X107·US·Common Stock·Healthcare - Biotechnology-13D/G

LXEO (LEXEO THERAPEUTICS INC) is held by 85 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($29.3M), RA CAPITAL MANAGEMENT, L.P. ($28.7M), Janus Henderson Group Ltd. ($28.5M). Net institutional sentiment: Mixed.

85
Holders
Avg rating(19 Elite)
$270M
Total Value
59% (93)
Fund Consensus
50 buying - 35 selling
LXEOSmart Money Verdict
View all
Held by 85 funds
19 elite
Who's Trading
InsiderTNTownsend Richard NolanSell $116KJul 1, 2026
InsiderOMOtero Jose ManuelSell $21KJul 1, 2026
InsiderTETamayo Louis EdwardSell $21KJul 1, 2026
InsiderBPBhalla Narinder PalSell $99KJul 1, 2026
ActivistBalyasny Asset Management L.P.Balyasny Asset Management L.P.9.7%May 15, 2026
ActivistPBParadigm BioCapital Advisors LP8.3%May 15, 2026
ActivistSUSUVRETTA CAPITAL MANAGEMENT, LLC7.7%Apr 13, 2026
InsiderTNTownsend Richard NolanSell $313KApr 6, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderTNTownsend Richard NolanSell $65KFeb 18, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
5.1M(+4.1%)$29.3M0.0%-41.74%
30
Unchanged
5M$28.7M0.3%-50.51%
0
Decreased
5M(-9.7%)$28.5M0.0%-51.22%
0
Increased
3.8M(+1.6%)$22M0.0%-56.28%
29
Increased
3.6M(+11.9%)$20.5M0.0%-49.17%
32
New
3M$17.3M0.0%-31.82%
39
Decreased
2.8M(-14.0%)$15.8M0.1%-41.65%
0
Increased
1.9M(+149.4%)$11.2M0.0%-39.09%
45
Decreased
1.9M(-43.2%)$10.8M0.1%-50.51%
0
Decreased
1.7M(-11.3%)$9.6M0.0%-27.53%
0
Increased
1.6M(+77.6%)$9.3M0.0%-12.99%
42
Decreased
1.6M(-2.8%)$9.1M0.0%+16.99%
0
Increased
1.5M(+4.7%)$8.7M0.0%-52.49%
29
Increased
1.1M(+27.9%)$6.3M0.0%-27.49%
34
Unchanged
904,959$5.2M0.0%-60.99%
0
New
577,192$3.3M0.0%-31.82%
37
Increased
493,666(+8.0%)$2.8M0.0%-52.37%
28
Increased
491,532(+206.7%)$2.8M0.0%-37.67%
42
Increased
465,515(+249.3%)$2.7M0.0%-38.48%
42
Increased
402,924(+187.4%)$2.3M0.0%-37.47%
42

Showing 1-20 of 93

1 / 5

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used